<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710188</url>
  </required_header>
  <id_info>
    <org_study_id>9936-104</org_study_id>
    <secondary_id>2015-004921-16</secondary_id>
    <nct_id>NCT02710188</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation</brief_title>
  <official_title>A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find a modified release oral tablet formulation for this
      drug, which will be safe and well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to develop a modified release oral tablet formulation that maintains
      plasma concentrations within the target therapeutic range, and is safe and tolerable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tlag</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the elapsed time from dosing at which HTL0009936 was first quantifiable in a concentration vs time profile (Tlag).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frel</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of relative bioavailability (Frel) of HTL0009936 MR prototype formulations compared to the IR reference formulation and, if applicable, MR prototype formulations in the fed state compared to fasted state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the elapsed time from dosing at which the maximum observed HTL0009936 concentration (Cmax) was apparent (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0009936 at 6 hours post dose (C6)</measure>
    <time_frame>6 hours post dose</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of HTL0009936 concentration at 6 hours post-dose (C6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-last)</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the area under the concentration versus time curve from time zero to the last measurable concentration (AUC(0-last))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf)</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the area under the concentration versus time curve from time zero to extrapolated to infinity (AUC(0-inf)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC%extrap</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of percentage of AUC(0-inf) extrapolated beyond last measured time point (AUC%extrap).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda-z</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the slope of the apparent elimination phase (Lambda-z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of the apparent elimination half-life (T1/2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose normalized AUC</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. In addition, if different dose levels of the same prototype are administered, dose normalized AUC (AUC/D) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose normalized Cmax</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. In addition, if different dose levels of the same prototype are administered, dose normalized Cmax (Cmax/D) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0009936 at 12 hours post dose (C12)</measure>
    <time_frame>12 hours post dose</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of HTL0009936 concentration at 12 hours post-dose (C12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0009936 at 24 hours post dose (C24)</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>The PK profiles of HTL0009936 Modified release oral prototype formulations in healthy CYP2D6 IM and EM subjects. Calculation of HTL0009936 concentration at 24 hours post-dose (C24)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>HTL0009936 modified release (MR) Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 5 different modified release formulations of HTL0009936, as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL00009936 immediate release (IR) fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936 modified release</intervention_name>
    <description>HTL0009936 modified release</description>
    <arm_group_label>HTL0009936 modified release (MR) Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936 immediate release</intervention_name>
    <description>HTL0009936 immediate release</description>
    <arm_group_label>HTL00009936 immediate release (IR) fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males &amp; females

          -  Aged 18 to 65 years

          -  Body mass index of 18.0 to 35.0 kg/m2

          -  CYP2D6 (intermediate or extensive metabolizer)

        Exclusion Criteria:

          -  Subjects with a resting heart rate (HR) &gt;90 bpm, and/or systolic blood pressure (BP)
             &gt;150 mmHg, and/or diastolic BP &gt;90 mmHg

          -  Subjects with QT interval corrected for heart rate using Fridericia's formula (QTcF)
             &gt;450 ms (males) or &gt;470 ms (females)

          -  Personal or family history of long QT syndrome or sudden death

          -  Subjects who are CYP2D6 (poor or ultra-rapid metabolizer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litza McKenzie, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

